Vera Therapeutics, Inc. Class A Common Stock (VERA) is a publicly traded Healthcare sector company. As of July 6, 2026, VERA trades at $40.78 with a market cap of $2.96B and a P/E ratio of -8.84. VERA moved +1.15% today. Year to date, VERA is -19.48%; over the trailing twelve months it is +74.21%. Its 52-week range spans $18.53 to $56.05. Analyst consensus is strong buy with an average price target of $80.09. Rallies surfaces VERA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Vera Therapeutics Shares Jump 1.72% Ahead of Pivotal FDA Atacicept Decision: Vera Therapeutics shares rose 1.72% today as investors positioned ahead of a pending FDA decision on its lead candidate, Atacicept. The outcome could determine U.S. approval for Atacicept’s B-cell targeting therapy in autoimmune disorders, directly impacting Vera’s commercialization timeline.
| Metric | Value |
|---|---|
| Price | $40.78 |
| Market Cap | $2.96B |
| P/E Ratio | -8.84 |
| EPS | $-4.66 |
| Dividend Yield | 0.00% |
| 52-Week High | $56.05 |
| 52-Week Low | $18.53 |
| Volume | 1.49M |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-299.62M |
| Gross Margin | 0.00% |
13 analysts cover VERA: 0 strong buy, 12 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $80.09.